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We conducted an observational cross-sectional study to
determine if the prevalence of hematologic and metabolic
abnormalities in chronic kidney disease (CKD) varied in
different ethnic groups. We used a CKD provincial database
where a complete data set at the time of registration was
available as well as an estimated glomerular filtration rate
(eGFR), which showed using the abbreviated MDRD formula
that the patients had CKD of stages 3–5. We included patients
with self-reported race of Caucasian, Oriental Asian, or South
Asian. Primary outcomes were the prevalence of at least one
of the following: anemia, hypocalcemia, hyperphosphatemia,
hyperparathyroidism, hypoalbuminemia, and three or more
laboratory abnormalities. All definitions were consistent with
K/DOQI guidelines. When compared with Caucasians,
Oriental Asians and South Asians had a higher prevalence of
many of the metabolic abnormalities during most stages of
CKD and were more likely to have any abnormality at all
levels of eGFR. The prevalence of three or more laboratory
abnormalities was higher in Oriental Asians at all stages and
in South Asians at some levels of eGFR. These results were
unchanged or exaggerated when controlled for age, gender,
diabetes, and a primary diagnosis of renal disease. Hence, it
appears that South Asians and Oriental Asians have more
laboratory abnormalities compared with Caucasians at most
levels of eGFR.
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Chronic kidney disease (CKD) is associated with increased
morbidity and mortality.1 The majority of deaths, both in
patients on renal replacement therapy and in pre-dialysis
patients, are due to cardiovascular events.2 The presence of
CKD has been shown to be a strong predictor of future
cardiovascular events, independent of traditional risk fac-
tors.2–4 It is not clear what accounts for this increased risk.
There are many metabolic abnormalities that develop with
progressive renal parenchymal damage, including calcium,
phosphate, parathyroid hormone, albumin, and hemoglobin
disturbances. It is not known which, if any, of these
abnormalities accounts for the increased cardiovascular
disease risk, or whether treating these abnormalities can
alter morbidity and mortality rates.
The metabolic abnormalities related to CKD (including
anemia, hypocalcemia, hyperphosphatemia, and hyperpara-
thyroidism) are associated with increased risk to the
patient.4–10 These risks are for the development of other
conditions (cardiovascular disease, susceptibility to infection,
bone disease), as well as progression of kidney disease to end
stage. However, at any given level of eGFR, there is much
heterogeneity in the severity of metabolic abnormalities. For
example, in CKD stage 5, 25% of patients have a hemoglobin
level above 110 g l1 (the recommended lower limit of the
target hemoglobin level).6,11 In end-stage renal disease
patients, 15% have normal bone biopsies with no evidence
of osteitis fibrosa cystica, aplastic bone disease, or osteoma-
lacia.12 These observations suggest a disconnect between the
filtration function of the kidney (as measured by GFR) and
the hormonal function of the kidney (as measured by various
metabolic abnormalities).
One possible explanation for such heterogeneity might be
ethnicity, which has been shown to affect various outcomes
in renal disease. Among peritoneal dialysis patients, Blacks
have significantly lower hemoglobin levels compared to
nonblacks despite receiving more treatment for anemia.13 At
each of CKD stages 3–5, anemic patients (defined as
hemoglobin o110 g l1) are more likely to be Caucasian
than they are Asian, with the majority of anemic patients
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being Caucasian.6 Furthermore, the long-term outcome of
patients on dialysis has been shown to be impacted by
ethnicity, with Asians having the best outcomes when
compared with age- and gender-matched controls on
dialysis.14,15
As metabolic abnormalities are associated with poor
outcomes, and ethnicity is known to predict survival, we
hypothesize that the number of metabolic abnormalities at
each stage of CKD may vary by ethnicity. We sought to
investigate this further by describing the metabolic abnorm-
alities in Asians and Caucasians at each stage of CKD, a
relationship that has yet to be reported in the literature.
RESULTS
Derivation of the cohort and characteristics
The entire database contains 15 346 registered patients. The
primary criteria for establishment of the cohort were the
availability of self-reported race (SRR), complete laboratory
data, and eGFR o60 ml per min per 1.73 m2 within the
prespecified date range, which were available for 5536
patients. Figure 1 describes the final derivation of the
analytical cohort, which excluded patients with SRR other
than Asian Orientals, South Asians, and Caucasians (e.g.
Filipino and First Nations); thus a total of 5322 patients were
available for analysis. Of note, analyses that included patients
without an available SRR were not significantly different than
those that excluded them; thus concerns about biased sample
are relatively minor. This is addressed further in the
discussion. The final cohort thus included 4047 Caucasians,
763 Oriental Asians, and 512 South Asians. The baseline
characteristics of the different SRR groups are shown in
Table 1. There are statistical differences between SRR for
baseline eGFR, age, sex, diabetes, and primary diagnosis of
kidney disease. The absolute differences in eGFR were small,
so we examined the ethnic mix at each level of eGFR. Figure 2
shows that the relative proportion of each SRR across levels
of eGFR is similar.
Laboratory abnormalities
The data describing the median values for calcium,
phosphate, parathyroid hormone, hemoglobin, and albumin
are shown in Table 2; Figure 3 displays similar data
graphically, using the prevalence of abnormalities as defined
by K/DQOI cut-offs, in percentages. The interaction terms
for SRR and eGFR were significant for PO4 and Alb (both
P-valueso0.03) but not for Hb, Ca, and intact parathyroid
hormone (iPTH); that is, the effect that race has on Hb, Ca,
and iPTH holds true at all levels of eGFR. The percentage of
patients who are anemic was significantly different across
SRR (Po0.01); Oriental Asians were 1.4 times more likely to
be anemic than Caucasians (95% confidence interval (CI) for
odds ratio (OR): 1.2–1.7), with no difference between South
Asians and Caucasians (OR: 1.0, 95% CI for OR: 0.8–1.3).
The results for hypocalcemia follow the same pattern as those
for anemia; the odds for hypocalcemia in Oriental Asians
were almost two times the odds in Caucasians (95% CI for
OR: 1.4–2.6). Hyperparathyroidism was also statistically
different between SRR (Po0.01), with both South Asians
(OR: 1.5, 95% CI for OR: 1.3–1.8) and Oriental Asians (OR:
2.2, 95% CI for OR: 1.8–2.7) more likely to be hyperpara-
thyroid than Caucasians.
The interaction terms for SRR and eGFR were significant
for hyperphosphatemia and hypoalbuminemia, suggesting
that the effect of SRR on these metabolic abnormalities may
vary at some levels of eGFR. The percentage of patients with
hyperphosphatemia was found to be different by SRR only at
eGFR levels of 15–30 and 30–45 ml per min per 1.73 m2 (both
P-values for SRR o0.01). For an eGFR of 15–30 ml per min
per 1.73 m2, South Asians were more likely to be hyper-
phosphatemia than Caucasians (OR: 1.8, 95% CI for OR:
1.2–2.7), with no difference between Oriental Asians and
Caucasians. For an eGFR of 30–45 ml per min per 1.73 m2,
Oriental Asians had higher odds of being hyperphosphatemia
than Caucasians (OR: 2.5, 95% CI for OR: 1.4–4.5), with no
difference between South Asians and Caucasians. The
percentage of patients with hypoalbuminemia was signifi-
cantly different by SRR only at eGFR levels of o15 and
15–30 ml per min per 1.73 m2 (both P-values for SRRo0.01).
For an eGFR of 15–30 ml per min per 1.73 m2, both Oriental
Asians and South Asians were 1.5 times more likely
hypoalbuminemia than Caucasians (95% CI for OR:
1.2–2.0), whereas for an eGFR of o15 ml per min per
1.73 m2, the odds were much lower in South Asians (OR: 0.4,
95% CI for OR: 0.3–0.7).
The association between the presence of ‘any laboratory
abnormality’ and SRR did not vary by eGFR levels (P-value
for the SRR/eGFR interaction ¼ 0.24). The proportions were
found to be different by SRR (Po0.01); specifically, both
Oriental Asians and South Asians were more likely to have
5322 patients form the study cohort
  214 patients excluded due to SRR other than 
Caucasian, Oriental Asian, or South 
                            Asian
5536 CKD patients with available SRR,
complete laboratory data, and first
documented eGFR60 ml per min per 1.73 m2
between
1 January 2000 and 31 December 2006
Figure 1 | Analytical cohort derivation from the Provincial
Registry of all CKD patients. SRR, self-reported race.
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‘any laboratory abnormality’ compared with Caucasians (OR
for Oriental Asians: 1.5 (95% CI: 1.3–1.9); OR for South
Asians: 1.9 (95% CI: 1.5–2.3)). For the presence of X3
metabolic abnormalities, our data suggested that its relation-
ship with SRR might differ at some levels of eGFR (P-value
for the SRR/eGFR interaction o0.01). For eGFR levels of
o15 and 45–60 ml per min per 1.73 m2, only Oriental Asians
were more likely to have X3 abnormalities than Caucasians
(OR at eGFRo15: 1.6 (95% CI: 1.1–2.4); OR at eGFR 45–60:
6.4 (95% CI: 2.5–16.2)). For an eGFR level of 15–30 and
30–45 ml per min per 1.73 m2, both South Asians and
Oriental Asians were more likely to have X3 metabolic
abnormalities than Caucasians. More specifically, at an eGFR
level of 15–30 ml per min per 1.73 m2, the OR for South
Asians was 1.7 (95% CI for OR: 1.1–2.5), and the OR for
Oriental Asians was 1.6 (95% CI for OR: 1.2–2.3). As for
eGFR level of 30–45 ml per min per 1.73 m2, the OR for South
Asians and Oriental Asians were 2.5 (95% CI for OR: 1.2–5.3)
and 3.4 (95% CI for OR: 1.9–6.0), respectively (see Figure 4).
Multivariate analysis
We also performed multivariate analyses (controlling for age,
sex, and the presence of diabetes) for each of the primary
outcomes described above. All of the above results held true
for these adjusted analyses. In addition, we controlled for the
primary diagnosis of renal disease, which resulted in the same
results except that at an eGFR of 15–30 ml per min per
1.73 m2, both Oriental and South Asians were more
hyperphosphatemic compared with Caucasians (as opposed
to South Asians alone in the unadjusted analysis).
DISCUSSION
This large cohort analysis of patients referred to nephro-
logists demonstrates that at the time of referral to a
nephrologist, at most levels of GFR, Oriental Asians and
South Asians have more observed laboratory abnormalities
than comparable Caucasians. The prevalence of these
abnormalities among different SRR in CKD patients has
not previously been described. Studies examining kidney
disease in Asian populations have been smaller than the
current analysis. To the extent that Asians have been shown
to have better outcomes on dialysis, and that laboratory
parameters selected here are associated with poor outcomes,
one might have assumed that Asians would also have better
laboratory parameters at each stage of CKD. Thus, the results
of this analysis in a referred cohort are unexpected.
As in all cohort studies, there are weaknesses. The link
between association and causation is difficult: Specifically, we
describe here an association of SRR with a different
prevalence of laboratory abnormalities by CKD stage, but
we cannot ascribe SRR as the sole cause of these differences.
Table 1 | Baseline characteristics of Caucasians, South Asians, and Oriental Asians
Ethnicity
Overall Caucasians Oriental Asians South Asians P-value
N 5322 4047 763 512
eGFR (mean±SD) 26.5±12.7 27.3±12.8 23.5±11.7 24.7±12.8 o0.01
eGFR level (%) o0.01
45–60 10 11 6 9
30–45 27 28 22 21
15–30 43 42 46 46
o15 20 19 26 24
Age (mean±SD) 67±15.2 67±14.9 68±15.4 61±16.7 o0.01
Male (%) 57 59 53 54 o0.01
Diabetes (%) 37 38 28 48 o0.01
Primary diagnosis o0.01
HTN 19 21 8 13
DM 24 25 14 30
GN 8 8 8 9
PCKD 3 4 1 2
Other 30 30 35 23
Unknown 16 11 34 23
DM, diabetes; GN, glomerulonephritis; HTN, hypertension; PCKD, polycystic kidney disease.




















Caucasian Oriental Asian South Asian
Figure 2 | Percentage of Oriental Asians, South Asians, and
Caucasians at each level of eGFR (ml per min per 1.73 m2).
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The issues of bias and confounders may interfere with the
conclusions described here. With respect to bias, the two
major issues include the potential bias of the modification of
diet in renal disease (MDRD) equation and that of referral
bias. There has been some suggestion in the literature that the
MDRD formula is biased in its estimation of GFR in Asians,
which is unlikely to explain our results and is discussed in
more detail below. To investigate the possibility of a referral
bias, in which Asians are referred to nephrologists at a
different stage of their disease compared with Caucasians, we
looked at the ethnic mix at each level of eGFR. The database
did not include specific information about the time from
identification of abnormal eGFR to nephrologist referral by
the primary care physician. As the relative mix of ethnicities
at each level of eGFR is similar (see Figure 2), a significant
referral bias is unlikely. Furthermore, as the prevalence of
abnormalities is higher at earlier stages of CKD, this would
also argue against referral bias. The slightly lower eGFR (of
approximately 2 ml per min per 1.73 m2) among Asians is
statistically significant, but within the ranges described not
likely clinically significant. In addition, there are issues of
SRR-related environmental factors (such as diet and lifestyle
differences) and SRR-related true genetic variability: the
impact of these different factors on the reported results
cannot be determined. There is currently no formal data
collection regarding diet habits for this cohort, due to the
primarily administrative nature of the data. This of course is
an area that requires further study.
The abbreviated MDRD formula has been shown in
Chinese patients to underestimate true GFR at higher levels
of eGFR and overestimate it at lower levels of eGFR, raising
the possibility that this may introduce bias.16 However, to
compare Asians with Caucasians, we are only interested in
the relative performance of the MDRD formula in these two
groups, not the absolute performance relative to a gold
Table 2 | The levels of Hb (g l1), Ca (mmol l1), PO4
(mmol l1), iPTH (pmol l1), and Alb (g l1) by eGFR level
among Caucasians, Oriental Asians, and South Asians with
CKD, reported as median values with interquartile range
Ethnicity
Caucasians Oriental Asians South Asians
Hb
Overall 120 (107–132) 116 (102–129) 117 (106–128)
eGFR: (45–60) 128 (114–140) 118 (109–138) 125 (115–140)
eGFR: (30–45) 124 (112–135) 120 (107–131) 120 (110–131)
eGFR: (15–30) 119 (106–129) 116 (103–129) 116 (103–124)
eGFR: o15 113 (101–125) 111 (97–125) 116 (103–128)
Ca
Overall 2.34 (2.26–2.43) 2.31 (2.22–2.41) 2.35 (2.27–2.44)
eGFR: (45–60) 2.35 (2.27–2.41) 2.33 (2.25–2.43) 2.38 (2.31–2.44)
eGFR: (30–45) 2.35 (2.27–2.42) 2.31 (2.23–2.41) 2.36 (2.27–2.43)
eGFR: (15–30) 2.34 (2.25–2.42) 2.31 (2.22–2.40) 2.34 (2.25–2.43)
eGFR: o15 2.35 (2.25–2.49) 2.32 (2.19–2.44) 2.35 (2.23–2.46)
PO4
Overall 1.28 (1.10–1.50) 1.36 (1.15–1.60) 1.40 (1.17–1.67)
eGFR: (45–60) 1.15 (1.02–1.32) 1.20 (1.05–1.40) 1.20 (1.10–1.40)
eGFR: (30–45) 1.19 (1.04–1.36) 1.27 (1.10–1.50) 1.28 (1.11–1.46)
eGFR: (15–30) 1.30 (1.11–1.52) 1.36 (1.17–1.58) 1.41 (1.21–1.70)
eGFR: o15 1.50 (1.22–1.82) 1.50 (1.23–1.85) 1.51 (1.28–1.90)
iPTH
Overall 11.6 (6.4–21.7) 15.9 (7.5–31.1) 19.5 (9.9–38.4)
eGFR: (45–60) 7.9 (4.5–11.6) 10.5 (5.7–28.0) 9.6 (4.9–20.0)
eGFR: (30–45) 9.1 (5.4–14.9) 9.9 (5.8–16.6) 13.0 (8.1–24.1)
eGFR: (15–30) 13.6 (7.3–24.4) 17.7 (8.0–31.2) 21.7 (11.7–38.3)
eGFR: o15 17.1 (8.1–36.2) 24.6 (12.5–45.9) 32.9 (14.5–62.0)
Alb
Overall 38 (35–41) 37 (33–40) 39 (34–41)
eGFR: (45–60) 39 (36–42) 38 (35–41) 39 (37–43)
eGFR: (30–45) 39 (36–42) 38 (35–41) 40 (37–42)
eGFR: (15–30) 38 (35–41) 37 (33–40) 38 (33–41)
eGFR: o15 36 (32–39) 36 (31–39) 38 (34–42)
eGFR in ml per min per 1.73 m2.
80 GFR: 45–60
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Figure 3 | The prevalence of metabolic abnormalities associated with CKD among Caucasians, South Asians, and Oriental
Asians at each eGFR level (ml per min per 1.73 m2). Stars denote a significant difference from Caucasians (*Po0.05). Hb,
anemia; Ca, hypocalcemia; PO4, hyperphosphatemia; iPTH, hyperparathyroidism; Alb, hypoalbuminemia.
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standard for GFR measurement. The abbreviated MDRD
formula is known to be less accurate in Asians than it was in
the population from which it was derived, comprised largely
of Caucasians.17,18 A modified version of the MDRD formula
(which uses a correction factor of 1.227 for Chinese race) has
been developed that performs similarly to the abbreviated
MDRD formula in the Caucasian population.17 We reana-
lyzed our results using this modified MDRD formula in our
Oriental Asian patients and found that this shifted some of
the Oriental Asian patients up a level of eGFR category (data
not shown). This analysis only exaggerated our results, given
that more patients were classified as having better kidney
function (eGFR) despite worse levels of biochemistry and
hematology. Therefore, any inaccuracy introduced by using
the abbreviated MDRD formula in our Asian patients does
not readily explain our results.
The differences in baseline characteristics seen in Table 1
raise the possibility of confounders. We controlled for known
predictors of the outcomes of interest (that is, the
abnormalities of laboratory values), including age, sex,
presence of diabetes, and primary renal diagnosis among
the three SRR groups in multivariate models. Our results
were either unchanged or exaggerated, thus these potential
confounders do not explain the finding of ethnic differences
in the prevalence of abnormalities. Of course, the possibility
of unknown confounders exists and cannot be addressed
further in this observational study.
Several medications used in the treatment of CKD are
titrated to our outcomes of interest, raising the possibility
that differences in medication use across SRR may explain the
observed differences in laboratory abnormalities. Our
database does not include information about medication
use at the time of referral to nephrologists, so direct
comparisons cannot be made. However, in British Columbia,
primary care physicians do not have access to erythropoietin
and, in general, do not prescribe phosphate binders or
vitamin D analogs. Therefore, it is highly unlikely that the
data that we have reported here, status at the time of referral
to nephrologists, are affected by the fact that the patients have
had significant exposure to medications known to affect the
outcomes of interest. Lastly, although there may be concern
regarding the relatively small proportion of patients main-
tained in the analytic cohort, the major driver of the loss of
patients for analysis is due to lack of reported SRR. However,
this was a predefined parameter of key interest and so those
without the parameter could not be included. This is typical
of many administrative data-set analyses. Furthermore, we
did undertake to ensure that the derived analytic cohort, with
SRR, was not systematically different from the complete
cohort (which includes those missing SRR) (data not shown).
As there were no substantial differences in the distribution of
variables by eGFR with the complete versus derived cohort,
we were satisfied that the lack of SRR was a random problem
related to variable attention to this detail and did not
constitute a source of bias.
Implications
The implications of our results are several. The K/DOQI
guidelines (on the diagnosis, identification, and evaluation of
CKD) defined the stages of CKD using estimated GFR. The
stages were derived from analyses of large population-based
databases that described greater prevalence and severity of
laboratory abnormalities.19 Our analysis raises the possibility
that the traditional GFR cut-offs for the stages of CKD may
not be equally appropriate for all races if they are meant to
reflect the prevalence of underlying laboratory abnormalities,
as a measure of overall kidney function. However, given that
a race-specific CKD stage classification would be cumber-
some and impractical, we would offer an alternative
hypothesis. The degree to which the eGFR stages represent
underlying kidney dysfunction (loss of both hormonal and
filtration function) may be race specific. Our results suggest
that there may be a disconnect between the filtration function
of the kidney (as measured by eGFR) and the hormonal and
excretory function of the kidney (as measured by laboratory
abnormalities), which appears to vary by race. Furthermore,
it may be that the prognostic value of these abnormalities
with CKD stage, and independent of CKD stage, is also race
dependent; future studies will need to examine this more
closely. Thus, therapeutic interventions and action plans may
need to be altered according to these findings, if they are
found to have implications with respect to outcomes. At the
current time, the relative importance of eGFR versus
laboratory abnormalities in prognostication is not clear.
Asians are noted to have better outcomes on dialysis. In
this large cohort, Asians were noted to have less-associated
comorbidity such as diabetes and hypertension (see
Table 1),14,15 and yet worse laboratory parameters at every
stage of CKD. We were unable to address rates of progression
in the current analysis due to data variability and complexity
but this will be further explored in subsequent studies using
appropriate data sets derived from this cohort. Future studies

























Figure 4 | The prevalence of X3 metabolic abnormalities
among Caucasians, South Asians, and Oriental Asians with
CKD across all eGFR levels (ml per min per 1.73 m2). Stars
denote a significant difference from Caucasians (*Po0.05).
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abnormalities and outcomes such as survival in the different
ethnic groups and time to renal replacement therapy.
Specifically, as has been described in blacks, it may be that
Asians have a more rapid progression to end-stage renal
disease; or because they have less diabetes and hypertension,
they do not have the competing risk of death or cardio-
vascular disease before dialysis, so they come to dialysis with
less comorbidity. Careful analysis with attention to con-
founders is required to understand the relationship between
the current findings and outcomes.
In conclusion, we demonstrate that, at the time of referral
to nephrologists in general, the prevalence of each laboratory
abnormality associated with CKD is more common in Asians
than Caucasians across all levels of eGFR; and that Asians are
more likely to have any laboratory abnormality or more likely
to have multiple laboratory abnormalities at all levels of
eGFR when compared with Caucasians. These findings have
not been described before. Given the paradox of better
survival of Asians, despite worse laboratory parameters at all
stages of CKD, many new questions have been raised by this
analysis. Further investigation into race-specific factors, both




This is an observational cross-sectional study examining the
prevalence of renal-specific laboratory abnormalities in a cohort of
patients at the time of registration in a provincial database.
Description of environment and derivation of the cohort
In British Columbia, all patients with CKD are registered in a
database at the time of referral to a nephrologist if they fulfill certain
criteria. These include referral to a nephrologist and the presence of
CKD (defined as estimated GFR o60 ml per min per 1.73 m2 or
diagnosis of kidney disease, assumed to be chronic based on biopsy,
ultrasound results, or clinical history; histological diagnoses are not
mandatory for the database). Estimated GFR was calculated using
the abbreviated MDRD formula.18 SRR is recorded and chosen from
a list that includes Oriental Asian, Caucasian, South Asian, First
Nation, Filipino, or other. At the initiation of the database (in the
year 2000), this field was not mandatory, and thus some patients
may or may not have had the field complete. For the purposes of the
analysis, we derived a cohort of patients who were identifiable, using
the SRR field, as Caucasian, South Asian, or Oriental Asian (as these
constitute the major ethnicities in British Columbia), and who were
enrolled between January 1, 2000, and December 31, 2006, and in
whom a complete data set upon registration was available (defined
as, in addition to SRR, serum creatinine, phosphate (PO4), calcium
(Ca), intact parathyroid hormone (iPTH), albumin (Alb), and hemo-
globin (Hb) levels).
All laboratory results are automatically uploaded to the database
and are thus available for each patient once registration occurs
(including historical values). Medications for CKD nondialysis
patients are paid for provincially (such as erythropoietic stimulating
agents, iron therapies, vitamin D analogs, and calcium supplements)
and are thus tracked after the patients are registered; no medications
at the time of registration would be paid for and are therefore not
captured in the database. Other baseline data collected include age,
gender, presence of diabetes, type of renal disease, and estimated
GFR (derived from standardized creatinine values and using MDRD
formula, see below for details). The primary renal diagnosis was
based on the clinical judgment of the nephrologists, as in most
registries. All patients signed informed consent. All required
information had already been collected and was contained in the
database. No further additional investigations were performed on
the patients for the purposes of this analysis.
Details regarding creatinine measurements and estimation
of GFR
Creatinine measurements at all laboratories in British Columbia
have been standardized with an isotope dilution mass spectrometry
reference for application in a province-wide estimated GFR
reporting initiative based on an isotope dilution mass spectrometry
traceable format of the MDRD formula.20 Therefore, although
creatinine measurements were performed in different laboratories,
they have been standardized, are directly comparable and therefore
used in the MDRD formula.
Primary outcomes of interest
The primary outcomes of interest for this analysis are the preval-
ence of anemia (Hb o110 g l1), hypocalcemia (corrected Ca
o2.1 mmol l1), hyperphosphatemia (PO4 41.8 mmol l1), hyper-
parathyroidism (iPTH greater than twice the upper limit of normal,
corresponding to 413 pmol l1), hypoalbuminemia (Albo36 g l1),
any laboratory abnormality, and X3 abnormalities. Definitions
for abnormalities were consistent with the currently established
K/DOQI guidelines for the management of CKD; however, only one
cut-off for iPTH was chosen for ease of analysis. Sensitivity analysis
for other levels was performed to ensure consistency of data (not
reported).
Baseline estimated GFR was categorized into o15, 15–30, 30–45,
and 45–60 ml per min per 1.73 m2; these cut-off points were chosen
to reflect the K/DOQI guidelines for CKD stages, but further
separated CKD stage 3 into two levels due to known deficiencies of
the MDRD formula (less accurate at eGFR levels above 45 ml per
min per 1.73 m2), and the widely held clinical belief that higher
levels of eGFR within stage 3 portend different outcomes.19
Statistical methods
Descriptive statistics are presented in percentage for categorical
variables, in mean with standard deviation or median with
interquartile range for continuous variables depending on distribu-
tion. Baseline demographics were compared using w2 test for
categorical variables and one-way ANOVA for continuous variables.
To investigate if the above dichotomized laboratory variables
vary among SRR groups at different levels of eGFR, we fitted several
logistic regression models with SRR, eGFR, and an SRR/eGFR
interaction term as predictors, and the dichotomized variables as the
outcomes. For those primary outcomes where the interaction terms
were found not to be statistically significant, we tested for the
differences in the primary outcome by SRR, controlling for eGFR.
On the other hand, if the interaction term was found to be
statistically significant, we constructed a number of contrasts that
allowed testing for the effect of SRR on the outcome at each level of
eGFR. Further comparisons were made between South Asians or
Oriental Asians and Caucasians if outcomes varied by SRR; the
estimated OR and its corresponding 95% CI were reported. This
Kidney International (2008) 74, 108–114 113
SJ Barbour et al.: CKD stages in different ethnic groups o r i g i n a l a r t i c l e
analytical approach was chosen to optimize the number of
comparisons performed and reduce the risk of committing type 1
errors. We also performed multivariate analyses adjusting for
potential confounders such as diabetes, age, sex, and primary
diagnosis of renal disease.
All tests were two-sided, with P-values less than 0.05 being
considered significant. All statistical analyses were performed in SAS
software, version 9.1 (SAS Institute, Cary, NC).
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